anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The intervention group will receive the Smartphone application at inclusion time and learn to use it in the hos-pital. When the families go home they will use the application and receive planned video consultations 2-3 times a week and the possibility to call the neonatal ward 24 hours a day all week whenever needed, until the infant gets full nutrition from the breast or bottle and gains weight. Parents will borrow a baby weight to weigh the baby at home.
Subjects with Major Depressive Disorder who were randomized to take 100mg of Bupropion SR in the morning and placebo in the evening for one week. Week 2 subjects were given 100mg dose of Bupropion morning and evening. Weeks 3 thru 12 received 150mg dose morning and evening. Week 1=dose level 1, 100 mg. Week 2=dose level 2, 200 mg. Weeks 3 - 12=dose level 3, 300 mg.
This group is defined by the use of a collagen hemostatic sponge and a self-adhesive dressing for the protection of the palatal donor area and fixed with an X-shaped suture to improve its stability in the area. A visual analog scale examination will be performed to evaluate the postoperative pain generated in the palate from day 1 to 14 and ending with the removal of this protection.
Patients in this arm will be administered intravenous potassium if they develop hypokalemia. As per CICU protocol 1-ml blood sample from already placed art-line or central venous line is sent for analysis of serum potassium concentration in all the immediate post operative patients. In the IVPR group, potassium will be given according to the hospital protocol through a central line. As per a previously established protocol and bioavailability data, repeat serum potassium will be sent 1 hour after replacement in the IVPR group.
Patients who have achieved remission of treatment resistant depression through an initial course of ECT (8 to 12 sessions) at the University of Kentucky will be identified by the ECT attending physician as a candidate for this study. If they elect to continue with maintenance ECT treatments which is the current standard of care, their depressive symptoms and cognitive functioning will be monitored accordingly.
Obtaining an aesthetic smile is one of the main reasons for the patient's demand for dental treatment, especially when it comes to gingival recession. However, there is a lack of evidence in the literature explaining the most appropriate type of treatment for multiple recessions in aesthetic areas. For unitary gingival recessions, the subepithelial connective tissue graft (SCTG) is considered the gold standard because it presents greater predictability for root coverage. However, it is associated with postoperative morbidity, limited amount of donor tissue, and longer surgical time. Thus, the search for a tissue substitute for SCTG is increasing. Currently, one of the possible autogenous soft tissue substitutes found in the market is the Mucograft® xenogeneic matrix (CM). The results with the use of CM are very promising, both for root coverage as well as for the gain of keratinized mucosa. The present study will consist of a double-blind parallel randomized clinical trial to compare SCTG (control group) and CM (test group) in the treatment of Miller's class I and II gingival recessions, multiple in aesthetic areas (central incisors, Lateral, upper canine). All measurements will be evaluated initially and in the periods of 3, 6, and 12 months after the surgical procedure.
The invention relates to a multipurpose biological safety disinfectant. The disinfectant contains acidic electrolyzed water, polyvinylpyrrolidone and modified chitosan. The hypochlorous acid in the acidic electrolyzed water has high molecular content, has the functions of sterilization and disinfection, and has high-efficiency broad-spectrum antibiosis. The polyvinylpyrrolidone is used as a stabilizer, so that the stability of the disinfectant can be improved, and the effective period of the disinfectant is prolonged to 18 months. The modified chitosan can form a water-based film on the surface of an object as an antibacterial agent, so that the antibacterial time of the disinfectant is prolonged. The biological safety disinfectant is slightly acidic and can be used for surface disinfection, and degradation products are safe and nontoxic.
Frailty is a known predictor of negative health outcomes. The role of frailty in predicting outcomes after traumatic brain injury (TBI), however, is unclear. This systematic review aimed to evaluate the association between frailty and adverse outcomes in patients with TBI. We identified relevant articles that investigated the relationship between frailty and outcomes in patients with TBI by searching PubMed/MEDLINE, Web of Science, Scopus, and EMBASE from inception until 23 March 2023. To evaluate the risk of bias in the included studies, we utilized the Newcastle-Ottawa Scale (NOS). In addition, quantitative synthesis and meta-analyses were performed. We identified 12 studies that met our inclusion criteria; three were prospective. Of included studies, eight had low risk, three had moderate risk, and one had high risk of bias. Frailty was significantly associated with death in five studies, with an increased risk of in-hospital death and complications observed in frail patients. Frailty was associated with longer hospital stays and unfavorable outcome measured by the Extended Glasgow Outcome Scale (GOSE) in four studies. The meta-analysis found that higher frailty significantly increased the odds of non-routine discharge and unfavorable outcome as measured by GOSE scores of 4 or lower. The pooled odds ratio (OR) for non-routine discharge, was 1.80, with a 95% confidence interval (CI) of 1.15-2.84; and for unfavorable outcome, it was 1.91, with a 95% CI of 1.09-3.36. The analysis, however, did not find a significant predictive role for frailty on death (30-day or in-hospital death). The OR for higher frailty and death was 1.42 with a 95% CI of 0.92-2.19. Frailty should be considered in the evaluation of patients with TBI to identify those who may be at increased risk of negative outcomes.
Described are general means and methods of diagnosing and treating the phenotypic spectrum as well as the overlapping clinical characteristics with several forms of inherited abnormal expression and/or function of the hPXR  gene. In particular, polynucleotides of molecular variant hPXR gene which, for example, are associated with insufficient metabolization and/or sensitivity of drugs, and vectors comprising such polynucleotides are provided. Furthermore, host cells comprising such polynucleotides or vectors and their use for the production of variant hPXR proteins are described. In addition, variant hPXR  proteins and antibodies specifically recognizing such proteins as well as transgenic non-human animals comprising the above-described polynucleotide or vectors are provided. Described are also methods for identifying and obtaining inhibitors for therapy of disorders related to the malfunction of the hPXR  gene as well as methods of diagnosing the status of such disorders.  Pharmaceutical and diagnostic compositions comprising the above-described polynucleotides, vectors, proteins, antibodies and inhibitors by the above-described method are provided. Said compositions are particularly useful for diagnosing and treating various diseases with drugs that are substrates, inhibitors or modulators of the hPXR gene product.
The preparation method of the Qiqing Baidu granules is characterized in that the medicine composition mainly comprises the following raw materials of 100g of scutellaria baicalensis, 100g of giant knotweed, 80g of Chinese pulsatilla root, 80g of lightyellow sophora root, 100g of isatis root, 60g of male fern rhizome, 40g of dyers woad leaf, 10-30g of inclusion agent beta-dextrin, 0.5-1g of aspartame serving as a flavoring agent, and 10-20g of HPMC (hydroxy propyl methyl cellulose) serving as a coating material as auxiliary materials: 400g of sucrose. The invention adopts inclusion agent: the beta-dextrin can include bitter components, can reduce and eliminate the foreign taste of the medicine, and can play a role in reducing the toxic and side effects and irritation of the medicine and improving the solubility of the medicine. Meanwhile, the taste of the medicine is better by adding the flavoring agent aspartame. The addition of HPMC as coating material can stabilize the granule, prevent moisture absorption of granule, and mask bitter taste of granule. The granule has the advantages of good stability, good solubility, good taste, and improved bioavailability. Is convenient for livestock and poultry to use.
Thyroid hormone has been shown to have both tumor-promoting and tumor-suppressing actions, which has led to significant debate over its involvement in the development of cancer. Proliferation, apoptosis, invasiveness, and angiogenesis are all aspects of cancer that are affected by the thyroid hormones T3 and T4, according to research conducted in animal models and in vitro experiments. The effects of thyroid hormones on cancer cells are mediated by many non-genomic mechanisms, one of which involves the activation of the plasma membrane receptor integrin αvβ3. Typically, abnormal amounts of thyroid hormones are linked to a higher occurrence of cancer. Both benign and malignant thyroid disorders were found to be associated with an increased risk of extra-thyroidal malignancies, specifically colon, breast, prostate, melanoma, and lung cancers. The purpose of this review was to shed light on this link to define which types of cancer are sensitive to thyroid hormones and, as a result, are anticipated to respond favorably to treatment of the thyroid hormone axis.
PURPOSE:To extract a tannin fraction, particularly a catechin compound in high yield, by eluting caffeine from a water-soluble extract of green tea leaves (Thea sinensis L.) or/and a gambir (Uncaria gambin Rubiaceae), extracting the residual liquid continuously with ether, and carrying out the above-mentioned operation at a low temperature under shielded light. CONSTITUTION:A water-soluble substance is extracted from green tea leaves (Thea sinensis L.) and/or a gambir (Uncaria gambin Rubiaceae) with a solvent, e.g. water, acetone-water or a lower alcohol-water, etc., and the resultant extract is then brought into contact with a polar solvent, e.g. chloroform, to elute caffeine converting into an inhibitory factor in extracting a catechin compound. The resultant residual liquid after eluting the caffeine is then continuously extracted with ether, and all the above-mentioned operations are carried out at a low temperature under shielded light, e.g. 40 deg.C or below, to suppress the decomposition of tannin and give advantageously the aimed tannin fraction, particularly catechin compound useful as an anitoxidant for improving the prevention quality of foods and cosmetics.
PURPOSE: To report the use of a subtenon's vancomycin injection for the treatment of subretinal abscess secondary to methicillin-resistant Staphylococcus aureus endogenous endophthalmitis.
METHODS: A 17-year-old man developed endogenous endophthalmitis with subretinal abscess in his right eye secondary to methicillin-resistant Staphylococcus aureus bacteremia from axillary necrotizing fasciitis. Despite prompt treatment with IV vancomycin and an intravitreal vancomycin injection, the patient displayed minimal improvement. The patient was subsequently treated with a subtenon's vancomycin injection. The injection technique is described in detail, as well as a review of the treatment options available for bacterial subretinal abscesses.
RESULTS: On presentation, examination revealed minimal vitritis and a large yellow subretinal abscess superotemporally extending close to the macula with subretinal fluid inferotemporally involving the macula. Four days postintravitreal vancomycin injection, the abscess remained stable and the patient developed an exudative detachment temporally. Vancomycin was injected superotemporally in the subtenon's space with no complications during the procedure or during his postoperative recovery. At seven days postinjection, the subretinal abscess and exudative retinal detachment resolved completely with necrosis at the area of previous abscess.
CONCLUSION: We present the first successful case of subtenon's vancomycin injection for the treatment of bacterial subretinal abscess. Our case demonstrates that subtenon's injection of antibiotics is a safe and effective nonsurgical management option for bacterial subretinal abscesses.
PURPOSE:A cosmetic having good feeling in use, wherein a metal lame agent is dispersed into aqueous gel of a carboxyvinyl polymer in good stability, obtained by blending the carboxyvinyl polymer with an alkali, the metal lame agent, a metal ion hindering agent, and water in a specific ratio. CONSTITUTION:Aqueous gel of a carboxyvinyl polymer is blended with a metal lame agent and a metal ion hindering agent, to give a cosmetic wherein the metal lame agent is dispersed into the aqueous gel in good shelf stability. The blending ratio is 0.1-5wt% carboxyvinyl polymer [e.g., High Vis Wako (Wako Junyaku), etc.], 0.1-1.5wt% inorganic, or organic alkali, 0.1-10wt% metal lame agent, 0.05-2wt% metal ion hindering agent (e.g., EDTA, hexametaphosphoric acid, etc.), and 50-99.65wt% water. The addition of the metal ion hindering agent provides the titled cosmetic not destroying the aqueous gel of the carboxyvinyl polymer.
A dental impression powder package and method for the preparation of material for making dental impressions. The package includes a bag that encloses dental impression powder and a valve that extends through the bag. The valve is selectively adjustable between an open state where the water is injectable into the bag and a closed state in which fluids are prevented from passing through the valve. The valve includes an open top end, a closed bottom end, a wall extending between the top and bosom ends, and a slit extending along a section of the wall. When the valve is open, the slit opens to permit fluid to be inserted into the bag. The slit closes to block fluid from passing through the slit in the valve while the contents of the bag are being mixed. A syringe is insertable into the valve to insert water into the bag and to extract air from the bag. In one embodiment of the present invention, the alginate mixture is extruded from the bag through the valve and into an impression tray.
The project is designed as a randomized controlled trial with approximately 750 subjects receiving a telemedicine intervention and approximately 750 receiving usual care. Eligibility requires having diabetes, being a Medicare beneficiary, and living in a medically underserved area. The project is conducted in New York City, in northern Manhattan (urban component), and in rural upstate New York through a consortion of participating institutions based at the State University of New York (SUNY) Upstate Medical University at Syracuse (rural component). Subjects are randomized to receive telemedicine case management or usual care for diabetes. The intervention utilizes a home telemedicine unit (HTU). The HTU is a specially designed, web-enabled device with a data port connected to a home glucometer and home blood pressure cuff whereby measurements obtained with these devices can be directly uploaded to a computer database. A diabetes nurse case manager interacts regularly with intervention participants through videoconference via the HTU.
PURPOSE:An activator, containing an aliphatic alcohol having carbon chain having an odd number of carbon atoms or a derivative thereof as an active constituent, and capable of effectively enhancing the water holding performance and activation of the skin by increase in blood stream. CONSTITUTION:A dermal activator containing a saturated or unsaturated aliphatic alcohol having an odd number of carbon atoms constituting the carbon chain, e.g. n-propyl alcohol or n-tricosyl alcohol, or a derivative thereof as an active constituent in an amount of 0.01-30wt% therein. Examples of the above-mentioned derivative include esterified aliphatic carboxylic acid, phosphoric acid, etc. and etherified aliphatic alcohol, polyhydric alcohol and saccharide. The above-mentioned activator is useful for preventing and normalizing the deterioration in water holding performance of the skin and various symptoms caused by poor blood circulation, e.g. chaps, cracks and roughened skin.
Arm 2: Participants randomized to the placebo arm will receive placebo capsules once daily for four weeks to be taken orally with a meal. Participants will then receive IM injections of saline (0.9% NaCI) at eight week intervals (at Weeks 4, 12, 20, 28, 36 and 44). On each dosing occasion placebo will be delivered in two, 2 mL injections, one in each gluteus maximus muscle. All participants will receive a total of six doses (12 IM injections).
A medical system for remote monitoring, analysis and prognosis of the patient's condition by series of at least first-lead electrocardiograms (ECGs) recorded for each patient from a plurality of observed patients, comprises: a unit for gathering in a database of the medical system for each of the observed patients a series of his ECGs marked with patient identifiers; a unit for extracting on doctor's request from the gathered database an ECG subset of a target group of patients, which are combined in said system into the target group in accordance with restrictions specified in the doctor's request and at least one of the identifiers in accordance with the examination purpose. A unit for clustering the extracted ECG subset sequentially combines all the ECGs extracted to the subset to at least one cluster based on the feature of similarity of their forms using a clustering method. A unit for determining an ECG form similarity measure in the space of ECG form features associates each ECG from the database of the medical system with a discretized ECG (DECG), which is a point having coordinates in at least one space of ECG form features. A unit for generating STANDARDS generates a corresponding STANDARD for each cluster. A unit for assessing the patient's condition assesses variation in the observed patient's condition over time by temporal variation in the distances between each newly received DECGs in the patient's DECG series and the assigned at least one STANDARD. A unit for predicting the observed patient's condition predicts the most probable future condition of the patient on the basis of "history of observations". A unit for imaging the patient's condition displays the dynamics of variation in distances of the patient's newly received ECGs as a displacement of cardiogram geometric paths between the assigned STANDARDS.
During the other study period, subjects receive the same dose of placebo tablets p.o instead of metformin. Subjects also receive Prednisone 20 mg 1.5x/d tablets p.o. for seven days.
1. Technical Result Increase in efficiency of treatment of diseases caused by elevated or abnormal levels of endothelin. 2. Essence A compounds of the formula I, in which Ar, B1, R1, Ry and m have any of the meanings defined herein, and their pharmaceutically acceptable salts; method for its production, pharmaceutical compositions containing them and use thereof for treatment of hypertension, pulmonary hypertension, congestive heart failure, atherosclerosis and other diseases. 3. Field of Application Medicine.
A method is disclosed for the treatment of hepadnavirus infection in animals. Animals infected with duck hepatitis B virus may be treated with the 2′,3′-dideoxynucleoside of adenine, guanine, hypoxanthine, 2,6-diaminopurine or various analogs of substituted purines. Several purine 2′,3′-­dideoxynucleosides inhibit duck hepatitis B virus in hepatocyte culture >99% at 1 µg/ml. Potent  in vivo  efficacy of the 2,6-diaminopurine 2′,3′-­dideoxynucleoside for clearance of duck hepatitis B virus from the sera of Pekin ducks is demonstrated. The selective effect on hepadnavirus replication by the purine 2′,3′-dideoxynucleosides is based on the discovery of an unexpected sensitivity of hepadnavirus to purine 2′,3′-dideoxynucleoside analogs. These compounds present a new antiviral therapy of acute or persistent hepadnavirus infections.
MCHB Care Coordination plus CHECK: includes all elements of MCHB care coordination, described above, plus the CHECK program. The CHECK program consists of a trained, behavioral health care team; an evidence-based treatment algorithm to classify risk for depression and anxiety (minimal, subclinical and clinical symptomatology) and guide treatment advancement \[Tier 1/selective: cognitive behavioral psycho-education; Tier 2/indicated: cognitive-behavioral prevention groups; Tier 3/treatment: individualized or group cognitive-behavioral treatment (CBT)\]; as well as structures and processes to support communication, coordination and data sharing between MCHB care coordinators and CHECK staff.
PURPOSE: Novel calpaines, their use and a production method thereof are provided. Further a screening method for new calpaine inhibitors and the use thereof are provided. CONSTITUTION: Calpaines belong to non-lysosome of cystein protease group, involve in Ca dependent signal-transference in eukaryote cells, therefore regulate physiologically cellular functions. In high concentration of Ca, calpaines are over-activated and cause pathological problems such as geriatric diseases. Thus, calpaine inhibitors are useful for treating such diseases. A method for preparing calpain inhibitors comprises the following steps of: isolating calpain nCL-3 from tissues or cells expressing enzyme nCL-3; measuring inhibitions of enzyme nCL-3 substrates and one or more enzyme calpain I and/or II substrates; and screening selective calpain inhibitors. nCL-3 calpain gene comprises SEQ ID NO: 1, allele mutants having homology of 60-100% with amino acids derived from SEQ ID NO: 1, homologues, or derivatives
Opioid tone may provide a way to identify people at risk of reward based eating, with more accuracy than self-report measures. Knowing such risk could improve treatment matching, and provide a biomarker to assess treatment progress. There is no direct measure of central opioid activity in humans, short of PET scans for opioid receptor binding. However, there is a promising indicator using an opioid antagonist such as naltrexone. Blocking opioid receptor releases the inhibitory opioidergic inputs to hypothalamic corticotropic releasing hormone (CRH) neurons, thus increasing CRH, and eventually cortisol in the blood. The extent of the cortisol rise in response to naltrexone might serve as an indicator of endogenous opioidergic tone. It is hypothesized that greater increases in cortisol indicate weaker endogenous opioid activity (by indicating a more complete opioid blockade). Salivary cortisol response to naltrexone may offer a relatively safe and unobtrusive way to measure endogenous opioidergic tone. We propose to test the reliability and validity of the naltrexone probe, taken at home, as a measure of endogenous opioidergic tone. In a previous study (Daubenmier et al, 2013), we administered a one time 50mg dose of naltrexone and examined nausea and cortisol responses. Results suggested that responses were higher in those who showed greater drive to eat. Here we examine a more direct measure of drive to eat, using the Yale Food Addiction Scale (YFAS), and test whether nausea and cortisol responses were associated with greater drive to eat, whether 50mg produced greater responses than 25 mg, and whether the responses were stable (highly related) when tested again one month later.
Diabetes medical group visits will be held at the Grady North DeKalb satellite clinic the third Thursday of the month starting in October 2009. There will be two cohorts of patients- English speaking patients and Spanish speaking patients. Each group will be scheduled for 4 2-hour group visits throughout a period of 9 months. These visits will be every 8 weeks for each group. During the visit, the patient will be seen by a physician, attend a diabetes education session, re-fill their diabetes medications, get orders for labs due, vaccinations and diabetes-related referrals.